Zobrazeno 1 - 10
of 144
pro vyhledávání: '"AL Dewar"'
Autor:
Kate Vandyke, Timothy P. Hughes, Stephen Fitter, Danijela Menicanin, L. B. To, Andrew C.W. Zannettino, AL Dewar
Publikováno v:
Leukemia. 23:2155-2159
Imatinib mesylate (Glivec/Gleevec, STI571; Novartis, Basel, Switzerland) is a 2-phenylaminopyrimidine-based ATP-competitive protein tyrosine kinase inhibitor, which at pharmacologically-achievable concentrations inhibits the activity of BCR–Abl,1 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3104e9e0ccbda384687bfd893baac011
https://doi.org/10.1038/leu.2009.150
https://doi.org/10.1038/leu.2009.150
Autor:
Stephen Fitter, L. Bik To, Andrew C.W. Zannettino, Kate Vandyke, Amanda N. Farrugia, Timothy P. Hughes, AL Dewar
Publikováno v:
Leukemia. 23:994-997
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2ffdd21d971bce2b10b7e790619abb5
https://doi.org/10.1038/leu.2008.356
https://doi.org/10.1038/leu.2008.356
Publikováno v:
Immunology & Cell Biology. 83:48-56
Imatinib is a tyrosine kinase inhibitor that has been reported to specifically inhibit the growth of bcr-abl expressing chronic myeloid leukaemia progenitors. This drug functions by blocking the ATP-binding site of the kinase domain of bcr-abl, and h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50290f479b7b97569dba503a6e751e20
https://doi.org/10.1111/j.1440-1711.2004.01296.x
https://doi.org/10.1111/j.1440-1711.2004.01296.x
Publikováno v:
Leukemia. 17:1713-1721
The antileukaemic tyrosine kinase inhibitor, imatinib, has been reported to inhibit specifically the growth of bcr-abl expressing CML progenitors at levels of 0.1-5.0 microM, by blocking the ATP-binding site of the kinase domain of bcr-abl. Inhibitio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235d6c0fad375afaba9f8e903fdb4b88
https://doi.org/10.1038/sj.leu.2403071
https://doi.org/10.1038/sj.leu.2403071
Publikováno v:
Cell Cycle. 4:851-853
Imatinib is a selective protein tyrosine kinase inhibitor currently used in the treatment of chronic myeloid leukaemia (CML). It specifically suppresses the growth of bcr-abl expressing CML progenitor cells by blocking the ATP-binding site of the kin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f828016f0205f34e8fe838fc00d3bd3
https://doi.org/10.4161/cc.4.7.1788
https://doi.org/10.4161/cc.4.7.1788
Autor:
Andrew C.W. Zannettino, AL Dewar, Natalie A. Sims, Kate Vandyke, Peter Diamond, Christopher G. Schultz, Stephen Fitter
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 25(8)
Dasatinib is a potent tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia in patients resistant or intolerant to imatinib mesylate. While designed to inhibit Abl and Src kinases, dasatinib shows multitarget effects, including inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5297ceaa387ce4bddca80e09b301e9a0
https://pubmed.ncbi.nlm.nih.gov/20225261
https://pubmed.ncbi.nlm.nih.gov/20225261
Publikováno v:
Blood. 115(4)
Imatinib mesylate is a rationally designed tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Although the efficacy and tolerability of imatinib are a vast improvement over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc978cc3d6726468a8c332233526ba97
https://pubmed.ncbi.nlm.nih.gov/19890095
https://pubmed.ncbi.nlm.nih.gov/19890095
Autor:
Stephen Fitter, Panagiota Kostakis, AL Dewar, Timothy P. Hughes, M M Roberts, Barrie Vernon-Roberts, Andrew C.W. Zannettino, L. Bik To, Kevin Lynch
Publikováno v:
Blood. 111(5)
Imatinib inhibits tyrosine kinases important in osteoclast (c-Fms) and osteoblast (platelet-derived growth factor receptor [PDGF-R], c-Abl) function, suggesting that long-term therapy may alter bone homeostasis. To investigate this question, we measu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763cfdcfa145201d2c9e044b6ab6207a
https://pubmed.ncbi.nlm.nih.gov/18042796
https://pubmed.ncbi.nlm.nih.gov/18042796
Autor:
Sally Martin, Stan Gronthos, AL Dewar, L. Bik To, Andrew C.W. Zannettino, Amanda N. Farrugia, Noemi Horvath
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(23)
Purpose: Multiple myeloma is an incurable hematologic malignancy characterized by increased bone marrow angiogenesis and extensive lytic bone disease. We have previously shown that elevated levels of stromal-derived factor-1α (SDF-1α) in peripheral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c7fccb6209f94c89f39f08309d0586
https://pubmed.ncbi.nlm.nih.gov/17145816
https://pubmed.ncbi.nlm.nih.gov/17145816
Autor:
Mark R. Condina, AL Dewar, Barrie Vernon-Roberts, L. Bik To, Amanda N. Farrugia, Andrew C.W. Zannettino, Timothy P. Hughes
Osteoclasts (OCs) are large multinucleated cells derived from progenitor cells of the monocyte-macrophage lineage. Signal transduction via the macrophage–colony-stimulating factor (M-CSF) receptor, c-fms, is essential for OC formation. Since we hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1b47aaac82ca2e70cb8d9461c1c3e7
https://hdl.handle.net/11541.2/129996
https://hdl.handle.net/11541.2/129996
